Parallelism: Considerations for the development, validation and implementation of PK and biomarker ligand-binding assays

Bioanalysis

Volumn 6, Issue 2, 2014, Pages 185-198

  Stevenson, Lauren F ^a   Purushothama, Shobha ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL PARAMETERS; BIOASSAY; BIOTRANSFORMATION; DECISION MAKING; INDICATOR DILUTION CURVE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; MINIMUM REQUIRED DILUTION; PARALLELISM; PK ASSAY; RECEPTOR BINDING ASSAY; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ANTIBODIES; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; HUMANS; LIGANDS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; VALIDATION STUDIES AS TOPIC;

EID: 84892740163     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.292     Document Type: Review

References (20)

1. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Bioanalytical Method Validation. European Medicines Agency, London, UK (2011).
2. Boterman M, Doig M, Breda M et al. Recommendations on the interpretation of the new European Medicines Agency Guideline on Bioanalytical Method Validation by Global CRO Council for Bioanalysis (GCC). Bioanalysis 4(6), 651-660 (2012).
3. DeSilva B, Garofolo F, Rocci M et al. 2012 White Paper on recent issues in bioanalysis and alignment of multiple guidelines. Bioanalysis 4(18), 2213-2226 (2012).
4. van Amsterdam P, Companjen A, Brudny-Kloeppel M et al. The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency Guideline on Bioanalytical Method Validation. Bioanalysis 5(6), 645-659 (2013).
5. Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312-328 (2006).
6. Valentin MA, Ma S, Zhao A, Legay F, Avrameas A. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J. Pharm. Biomed. Anal. 55(5), 869-877 (2011).
7. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003).
8. Myler HA, Given A, Kolz K, Mora JR, Hristopoulos G. Biotherapeutic bioanalysis: a multi-indication case study review. Bioanalysis 3(6), 623-643 (2011).
9. Stevenson L, Kelley M, Gorovits B et al. Consensus and recommendations of the L2 Global harmonization team, large molecule specific assay operation for ligand binding assays in support of pharmacometrics. AAPS J. doi:10.1208/s12248-013-9542-y (2013) (Epub ahead of print).
10. Myler HA, McVay S, Kratzsch J. Troubleshooting PEG-hGH detection supporting pharmacokinetic evaluation in growth hormone deficient patients. J. Pharmacol. Toxicol. Methods 61(2), 92-97 (2010).
11. Myler HA, Phillips KR, Dong H et al. Validation and life-cycle management of a quantitative ligand-binding assay for the measurement of Nulojix®, a CTLA-4-Fc fusion protein, in renal and liver transplant patients. Bioanalysis 4(10), 1215-1226 (2012).
12. Stevenson L, Garofolo F, DeSilva B et al. 2013 White Paper on recent issues in bioanalysis: 'hybrid'-the best of LBA and LCMS. Bioanalysis 5(23), 2903-2918 (2013).
13. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J. 13(1), 99-110 (2013).
14. Gorovits B, Alley, SC, Bilic S et al. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5(9), 997-1006 (2013).
15. Ciotti S, Purushothama S, Ray S. What is going on with my samples? A general approach to parallelism assessment and data interpretation for biomarker ligand-binding assays. Bioanalysis 5(16), 1941-1943 (2013).
16. Gottschalk PG, Dunn JR. Measuring parallelism, linearity, and relative potency in bioassay and immunoassay data. J. Biopharm. Stat. 15(3), 437-463 (2005).
17. Hammond GW, Noble GR, Smith SJ. Lack of parallelism in antibody responses as measured by enzyme immunoassay after infection due to influenza virus A/USSR/77 (H1N1). J. Infect. Dis. 146(6), 827 (1982).
18. Hurley WL, Rejman JJ. beta-Lactoglobulin and alpha-lactalbumin in mammary secretions during the dry period: parallelism of concentration changes. J. Dairy Sci. 69(6), 1642-1647 (1986).
19. O'Connor KA, Brindle E, Shofer JB et al. Statistical correction for non-parallelism in a urinary enzyme immunoassay. J. Immunoassay Immunochem. 25(3), 259-278 (2004).
20. Plikaytis BD, Holder PF, Pais LB, Maslanka SE, Gheesling LL, Carlone GM. Determination of parallelism and nonparallelism in bioassay dilution curves. J. Clin. Microbiol. 32(10), 2441-2447 (1994).